Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance

Clinical Microbiology and Infection

Volumn 20, Issue 3, 2014, Pages

  Cohen, M J ^a   Block, C S ^a   Moses, A E ^a   Nir Paz, R ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Carbapenem antibiotics; Pseudomonas aeruginosa; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; OFLOXACIN; QUINOLONE DERIVATIVE; UREIDOPENICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CASE CONTROL STUDY; MORTALITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ADULT; AGED; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTIONS; VERY ELDERLY;

PSEUDOMONAS AERUGINOSA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84893756216     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12362     Document Type: Article

References (30)

1. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011; 19: 419-426.
2. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS II. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 2011; 31: 598-608.
3. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
4. Miliani K, L'Heriteau F, Lacave L, Carbonne A, Astagneau P. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern france. J Hosp Infect 2011; 77: 343-347.
5. Johnson JK, Smith G, Lee MS et al. The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis 2009; 200: 900-905.
6. Royal decree of April 26, 1999. Creation of belgian antibiotic coordination committee (bapcoc). Belgisch staatsblad July 31, 1999. 1999.
7. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177.
8. Stelling J, O'Brien TF. Whonet 5.4: software for the management and analysis of microbiology laboratory results. Boston, MA: WHO Collaborating Centre for Surveillance of Antimicrobial Resistance, 2007. http://www.who.int/drugresistance/whonetsoftware.
9. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twentieth informational supplement; m100-s20. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
10. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27: 893-900.
11. Bhat S, Fujitani S, Potoski BA et al. Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents 2007; 30: 458-462.
12. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2002; 50: 299-301.
13. van de Sande-Bruinsma N, Grundmann H, Verloo D et al. Antimicrobial drug use and resistance in europe. Emerg Infect Dis 2008; 14: 1722-1730.
14. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 1152-1156.
15. Steinke D, Davey P. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clin Infect Dis 2001; 33 (Suppl. 3): S193-S205.
16. Gbaguidi-Haore H, Dumartin C, L'Heriteau F et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother 2013; 68: 461-470.
17. Vernaz N, Huttner B, Muscionico D et al. Modelling the impact of antibiotic use on antibiotic-resistant escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011; 66: 928-935.
18. Vojtova V, Kolar M, Hricova K et al. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. New Microbiol 2011; 34: 291-298.
19. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 1983-1986.
20. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group a streptococci in finland. Finnish study group for antimicrobial resistance. N Engl J Med 1997; 337: 441-446.
21. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-542.
22. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 (Suppl. 2): ii11-ii21.
23. Cook PP, Gooch M, Rizzo S. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study. Antimicrob Agents Chemother 2011; 55: 5597-5601.
24. McDougall DA, Morton AP, Playford EG. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in queensland, australia. J Antimicrob Chemother 2013; 68: 457-460.
25. Nicolau DP, Carmeli Y, Crank CW et al. Carbapenem stewardship: does ertapenem affect pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents 2012; 39: 11-15.
26. Sousa D, Castelo-Corral L, Gutierrez-Urbon JM et al. Impact of ertapenem use on Pseudomonas aeruginosa and acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 2013; 68: 1917-1925.
27. Park YS, Lee H, Chin BS et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems. J Hosp Infect 2011; 79: 54-58.
28. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50: 43-48.
29. Patel N, McNutt LA, Lodise TP. Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 2933-2936.
30. Jacoby GA. Ampc beta-lactamases. Clin Microbiol Rev 2009; 22: 161-182.